What question did this study set out to answer?

This investigation aims to assess the prevalence and implications of hyperferritinemia in metabolic dysfunction-associated steatotic liver disease.

March 26, 2026Liver International0 citations

View Full Paper

Prevalence and Characteristics of Hyperferritinemia in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Meta‐Analysis

MSMatheus Romano de Souza LLLuan C. V. Lima CVCristiane Alves Villela‐Nogueira

Key Points

This investigation aims to assess the prevalence and implications of hyperferritinemia in metabolic dysfunction-associated steatotic liver disease.
Conducted a meta-analysis on existing studies reporting on hyperferritinemia in MASLD.
Analyzed characteristics associated with hyperferritinemia and severity of metabolic dysfunction.
Identified correlations with liver injury among MASLD patients.
Approximately 25% of patients with MASLD exhibit hyperferritinemia.
Patients with hyperferritinemia show signs of more severe metabolic dysfunction.
Hyperferritinemia serves as a useful biomarker for identifying higher-risk patients.

Abstract

HF is present in approximately one in four patients with MASLD and identifies a subgroup with more severe metabolic dysfunction and liver injury. These data highlight SF as a simple, accessible biomarker that may help identify higher-risk MASLD phenotypes.

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

Prevalence and Characteristics of Hyperferritinemia in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Meta‐Analysis

Key Points

Abstract

Cite This Study